Biopure

About Biopure

Biopure Corporation develops, manufactures and markets oxygen therapeutics, a new class of pharmaceuticals that are administered intravenously to increase oxygen transport to the body's tissues. Using our patented and proprietary technology, we have developed and manufacture two products: Hemopure® (HBOC-201) [hemoglobin glutamer - 250 (bovine)] for human use, and Oxyglobin® (HBOC-301) [hemoglobin glutamer - 200 (bovine)] for veterinary use. Hemopure is being sold in South Africa for the treatment of adult surgical patients who are acutely anemic and for eliminating, reducing or delaying the need for allogenic red blood cell transfusion in these patients. A marketing authorization application for Hemopure is pending in the United Kingdom, also for a surgery indication.

We have been developing Hemopure for the treatment of patients with cardiovascular ischemia and supporting the U.S. Navy's government-funded development of the product for out-of-hospital treatment of trauma patients in hemorrhagic shock. To exploit the body of preclinical and clinical information we have involving anemia, we are now beginning development for use of Hemopure in anemic cancer patients and end-of-life patients.

Oxyglobin, our veterinary product for the treatment of anemia in dogs, is the only oxygen therapeutic approved by the U.S. Food and Drug Administration (FDA) and the European Commission. We have sold approximately 200,000 units of Oxyglobin.

We are headquartered and operate a cGMP manufacturing facility in Cambridge, Massachusetts.